



TEW

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/659,735

Filing Date

September 9, 2003

First Named Inventor

Antoni KOZLOWSKI

Art Unit

1618

Examiner Name

Blessing M. FUBARA

Attorney Docket Number

SHE0064.00

## ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐

Reply to Missing Parts/  
Incomplete Application

☐

Reply to Missing Parts  
under 37 CFR 1.52 or 1.53

☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐

Petition to Convert to a  
Provisional Application

☐

Power of Attorney, Revocation

☐

Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

Remarks

☐

After Allowance Communication to TC

☐

Appeal Communication to Board  
of Appeals and Interferences

☐

Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

☐

Proprietary Information

☐

Status Letter

☒

Other Enclosure(s) (please identify  
below):

PTO/SB/08B; 7 Cited References; and  
Return Receipt Postcard

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Nektar Therapeutics

Signature

*Mark A. Wilson*

Printed name

Mark A. Wilson

Date

October 18, 2006

Reg. No.

43,275

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

*Anna Tran*

Typed or printed name

Anna Tran

Date

10/18/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Antoni KOZLOWSKI )

Atty. Docket No.: SHE0064.00 )

Examiner: Blessing M. FUBARA )

Application No.: 10/659,735 )

Group Art Unit: 1618 )

Filed: 09/09/2003 )

Title: METHOD FOR PREPARING WATER- )  
SOLUBLE POLYMER DERIVATIVES )  
BEARING A TERMINAL )  
CARBOXYLIC ACID )

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on 10/18/2006

Signed: 

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:



within three months of the filing date of a national application or an RCE; within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action

Attorney Docket No. SHE0064.00

on the merits (whichever event occurs last).

- ☐ Attached is Check No. \_ in the amount of \$0.
- ☐ Please charge the amount of \$\_\_\_ to Deposit Account 500348
- ☒ If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.

Respectfully submitted,

NEKTAR THERAPEUTICS

Dated: October 18, 2006

By:

Mark A. Wilson

Mark A. Wilson  
Reg. No. 43,275

NEKTAR THERAPEUTICS  
150 Industrial Road  
San Carlos, CA 94070  
(650) 631-3100



<b>Form PTO/SB/08B (Modified)</b>  <b>Information Disclosure Statement By Applicant</b>  <i>(Use Several Sheets if Necessary)</i>	<b>Atty Docket No.:</b> SHE0064.00	<b>Application No.:</b> 10/659,735
	<b>Applicant:</b> Antoni KOZLOWSKI	
	<b>Filing Date:</b> 09/09/2003	<b>Group:</b> 1618

**Other Documents**

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	A	NEKTAR™ - Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, pp. 1-20, (Catalog – 2003).
	B	NOF CORPORATION, “PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals”, pp. 1-46, (Catalogue 2003-1 <sup>st</sup> ).
	C	NOF CORPORATION, “PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals”, pp. 1-50, (Catalogue 2003-2 <sup>nd</sup> ).
	D	SHEARWATER POLYMERS, INC., p. 2-49, (Catalog - March, 1995).
	E	SHEARWATER POLYMERS, INC., Polyethylene Glycol and Derivatives, pp. 1-53, (Catalog – July, 1997).
	F	SHEARWATER POLYMERS, INC., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, pp. 1-50, (Catalog - 2000).
	G	SHEARWATER CORPORATION, Polyethylene Glycol and Derivatives for Biomedical Applications, pp.1-17, (Catalog – 2001).
<b>Examiner:</b>		<b>Date Considered:</b>

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.